paclitaxel

P1, N=27, Active, not recruiting, Institut Paoli-Calmettes | Recruiting --> Active, not recruiting

P=N/A, N=15, Completed, National University Hospital, Singapore | Recruiting --> Completed | N=33 --> 15

Encapsulated paclitaxel (PTX), otherwise restricted by BBB impermeability, is effectively delivered to intracranial tumors and induces reactive oxygen species-driven immunogenic cell death...Synergizing with the pathogen-mimetic characteristics of BEVs, these signals also elicit an approximately 2-fold increase in intratumoral CD8⁺ T-cell infiltration, overcome immune exclusion, and achieve durable tumor control with extended survival in orthotopic GBM models. Accordingly, this virus-bacteria-drug biohybrid strategy enables targeted brain delivery while simultaneously amplifying antitumor immunity, offering a promising and translatable approach for GBM treatment.

Adjuvant therapy comprised paclitaxel (175 mg/m²) plus cisplatin (75 mg/m²) every 3 weeks for six cycles, combined with pembrolizumab (200 mg every 3 weeks). To our knowledge, this is one of the first reported cases of pembrolizumab combined with platinum-based chemotherapy in the adjuvant setting for primary triple-negative NEBC. This case provides hypothesis-generating evidence for chemo-immunotherapy in this rare, high-grade histologic subtype.

CD4 deficient mice were significantly less hypersensitive than CD4 + sufficient mice with a stronger reduction in the sHD group. Although higher cumulative doses are associated with increased CIPN risk, our results suggest that the concentration and frequency of PTX more directly influence DRG immune programming, and that this immune shaping modulates CIPN severity.

Patients received either AC-T (doxorubicin/cyclophosphamide followed by paclitaxel; n = 70) or TAC (docetaxel/doxorubicin/cyclophosphamide; n = 48). These findings support individualized regimen selection based on patient profile and tumor biology. Prospective studies are needed to refine region-specific treatment strategies.

In this analysis, gBRCAmut carriers treated with KN522 achieved remarkably high pCR rates. The observed 40% hospitalizations, primarily due to NF, highlights the need for supportive care optimization, including G-CSF consideration.

P=N/A, N=200, Recruiting, National University Hospital, Singapore | N=80 --> 200

P2/3, N=172, Not yet recruiting, Gruppo Oncologico Del Nord Ovest

Although paclitaxel and lenvatinib have been used as drug treatments, combination therapy with dabrafenib and trametinib has recently been reported to be effective. Furthermore, lenvatinib, a molecularly targeted agent, shows limited efficacy against ATC and is associated with frequent adverse events. In contrast, combination therapy with dabrafenib and trametinib is considered an effective therapeutic option for patients with BRAF V600E mutation-positive ATC, when appropriate management and monitoring are implemented.

Our results indicate that NACT can alter active DNA demethylation markers. Breast cancer patients with prolonged DFS had lower leukocyte 5-mdC and higher urinary 5-mdC levels before chemotherapy. Thus, assessing 5-mdC in these minimally invasive biospecimens may provide prognostic information for breast cancer patients undergoing NACT.

 Switching CDK4/6i and ET conferred a statistically significant improvement of PFS in patients with progression or recurrence on prior CDK4/6i-containing therapy. These findings underscore the variability in survival outcomes based on post-CDK4/6i therapy choices in HR+/HER2- MBC, with promising evidence for rechallenging strategies.